ArticleBMC immunology2025
Induction of high numbers of T
Article in BMC immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Targeted hyperthermia therapy (THT) using gold nanorods remodels the tumor microenvironment to sensitize murine microsatellite-stable colorectal cancer to immune checkpoint blockade.Journal of nanobiotechnology · 2026Article
- Rapid Resolution of Psoriasis Following Low-Dose Interleukin-2 Monotherapy: A Case Report.Biologics : targets & therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPsoriasis is a prevalent autoimmune skin disorder; however, the mechanism of its pathogenesis remains fully understood. The imbalance of regulatory T (T AIM OF THE WORK: Given that IL-2/IL-12 complex is considered as an immune modulator for antigen-activated lymphocyte proliferation, this study aimed to compare the immunophenotypic, clinical, and histological effects of anti-IL-2/IL-2 complex to a low dose of free IL-2 on experimental psoriasis-like skin inflammation induced by imiquimod. MATERIALS AND
methodsThirty-five Balb/c male mice were left without treatment, or were received topical application of imiquimod (IMQ, 3.125 mg/mouse) to induce psoriasis-like skin inflammation, and then the mice were treated with intraperitoneal (i.p.) injection of 100 µL containing anti-IL-2/IL-2 complex (2.5 µg /0.5 µg/mouse), or topical steroids (62.50 mg/mouse), or low dose of free IL-2 (i.p.; 0.5 µg/mouse). The expression levels of CD4, CD25, and Foxp3 in the leukocytes were assessed by multiparametric flow cytometry. The effects of different treatments on the histology and pathology of the induced psoriasis were also assessed.
resultsIMQ-induced hyperkeratosis, parakeratosis and mild papillomatosis with the retained nuclei in the keratin layer, whereas acanthosis with exocytosis was prominent in the epidermal layer. Lymphocyte infiltration was profusely all over the dermis. Additionally, there were some degrees of Munro micro abscesses were observed in the keratin layer with a collection of neutrophils in the group treated with standard betamethasone cream which showed mild improvement clinically, histopathological with no significant difference between this group and the naïve and positive control groups. After 7 days from the onset of treatment, we found that treatment of mice with anti-IL-2/IL-2 complex decreased the thickness of the epiderms as compared to their groups. Furthermore, the relative number of CD4 IN
conclusionAnti IL-2/IL-2 complex therapy effectively ameliorated the clinical manifestations of psoriasis, with no apparent side effects, providing a new strategy for treating psoriasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.